TY - JOUR
T1 - EphA4 receptor forward signaling inhibits glucagon secretion from α-cells
AU - Hutchens, Troy
AU - Piston, David W.
N1 - Funding Information:
Funding. The majority of this study was supported by National Institutes of Health (NIH) grants DK098659 and DK098838. Flow cytometry was performed utilizing the Vanderbilt Medical Center Flow Cytometry Shared Resource Core, supported by NIH grants CA68485 and DK058404. Plasma hormones were analyzed by the Vanderbilt Hormone Assay & Analytical Services Core, supported by NIH grants DK059637 and DK020593. T.H. is a fellow in the Vanderbilt Medical Scientist Training Program, supported by the NIH grant GM07347.
Publisher Copyright:
© 2015 by the American Diabetes Association.
PY - 2015/11
Y1 - 2015/11
N2 - The loss of inhibition of glucagon secretion exacerbates hyperglycemia in type 1 and 2 diabetes. However, the molecular mechanisms that regulate glucagon secretion in unaffected and diabetic states remain relatively unexplained. We present evidence supporting a new model of juxtacrine-mediated regulation of glucagon secretion where neighboring islet cells negatively regulate glucagon secretion through tonic stimulation of a-cell EphA receptors. Primarily through EphA4 receptors, this stimulation correlates with maintenance of a dense F-actin network. In islets, additional stimulation and inhibition of endogenous EphA forward signaling result in inhibition and enhancement, respectively, of glucagon secretion, accompanied by an increase and decrease, respectively, in α-cell F-actin density. Sorted a-cells lack endogenous stimulation of EphA forward signaling from neighboring cells, resulting in enhanced basal glucagon secretion as compared with islets and the elimination of glucose inhibition of glucagon secretion. Restoration of EphA forward signaling in sorted a-cells recapitulates both normal basal glucagon secretion and glucose inhibition of glucagon secretion. Additionally, a-cell-specific EphA4-/- mice exhibit abnormal glucagon dynamics, and EphA4-/- α-cells contain less dense F-actin networks than EphA4+/+ α-cells. This juxtacrine-mediated model provides insight into the functional and dysfunctional regulation of glucagon secretion and opens up new therapeutic strategies for the clinical management of diabetes.
AB - The loss of inhibition of glucagon secretion exacerbates hyperglycemia in type 1 and 2 diabetes. However, the molecular mechanisms that regulate glucagon secretion in unaffected and diabetic states remain relatively unexplained. We present evidence supporting a new model of juxtacrine-mediated regulation of glucagon secretion where neighboring islet cells negatively regulate glucagon secretion through tonic stimulation of a-cell EphA receptors. Primarily through EphA4 receptors, this stimulation correlates with maintenance of a dense F-actin network. In islets, additional stimulation and inhibition of endogenous EphA forward signaling result in inhibition and enhancement, respectively, of glucagon secretion, accompanied by an increase and decrease, respectively, in α-cell F-actin density. Sorted a-cells lack endogenous stimulation of EphA forward signaling from neighboring cells, resulting in enhanced basal glucagon secretion as compared with islets and the elimination of glucose inhibition of glucagon secretion. Restoration of EphA forward signaling in sorted a-cells recapitulates both normal basal glucagon secretion and glucose inhibition of glucagon secretion. Additionally, a-cell-specific EphA4-/- mice exhibit abnormal glucagon dynamics, and EphA4-/- α-cells contain less dense F-actin networks than EphA4+/+ α-cells. This juxtacrine-mediated model provides insight into the functional and dysfunctional regulation of glucagon secretion and opens up new therapeutic strategies for the clinical management of diabetes.
UR - http://www.scopus.com/inward/record.url?scp=84962197450&partnerID=8YFLogxK
U2 - 10.2337/db15-0488
DO - 10.2337/db15-0488
M3 - Article
C2 - 26251403
AN - SCOPUS:84962197450
SN - 0012-1797
VL - 64
SP - 3839
EP - 3851
JO - Diabetes
JF - Diabetes
IS - 11
ER -